Novogen initiates Phase I trial of cardiovascular drug

This drug is designed to reduce restenosis or re-blocking of arteries after surgery to clear blockages, commonly involving insertion of arterial stents. The study is being conducted in association with Bond University, Queensland, Australia under the direction of clinical pharmacologist, Laurie Howes. The current study is the first step in the clinical development of the drug. It will involve initial testing in a small number of healthy human volunteers to determine the safety and kinetics of NV-27 in humans.

Laurie Howes, principal investigator of this study, said: “We are very pleased to be involved in the development of this compound which has the potential to assist in the management of restenosis in coronary artery stenting. We have extensive experience in the kinetics and safety profile of this class of compounds and expect that the Phase I goals of safety and tolerability will be met in this study.”